
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Holdings Inc is exhibiting strong financial performance, highlighted by a gross margin of 71.1%, which represents a year-over-year increase of 230 basis points and exceeds consensus expectations. The company has projected revenue for 2025 to be between $870 million to $880 million, indicating a year-over-year growth rate of 16%-18%, alongside a consistent trend of over 20% year-over-year revenue growth for five consecutive quarters. Additionally, anticipated improvements in EBITDA margins and contributions from pricing and mix enhancements further bolster the company's positive outlook.
Bears say
iRhythm Holdings Inc faces a challenging outlook primarily due to anticipated growth slowing to the low-teens, coupled with expectations of flat pricing in 2026, which could limit revenue expansion. The company is also susceptible to multiple risks, including adverse changes in commercial reimbursement practices, heightened competition in the cardiac monitoring market, and the potential failure of key product launches like ZioAT to generate anticipated market traction. Furthermore, the presence of substantial operating expenses combined with risks related to sales execution and the possibility of additional equity offerings adds to the overall financial uncertainty surrounding the company.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares